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Abstract
Tonic basal release of nitric oxide (NO) by vascular endothelial cells controls blood pressure (BP) in the basal state. In the present study, we
showed how serum and local angiotensin converting enzyme (ACE) alters during development of hypertension in chronic nitric oxide synthase
blockade, a non-renin-dependent model of hypertension. Four experiments were performed in which animals were given Nω-nitro-l-arginine
methyl ester (l-NAME) (50 mg kg−1) for 2, 4, 8 and 12 weeks. The control group rats received tap water. The ACE activity in serum, aorta,
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deart, kidney and lung was analyzed by high performance liquid chromatography (HPLC) and the structural change in aorta was investigated
y measurement of cross-sectional area (CSA). Significant elevation of systolic blood pressure developed in chronically NO-blocked rats
ompared to controls. These results indicated that ACE activity in aortae and heart was gradually increased during development of hypertension
nd was more pronounced at higher blood pressure. Furthermore, there was a positive correlation between aortic cross-sectional area and
levation of blood pressure. These observations highlight the importance of the local ACE particularly in organs regulating hypertension (aorta
nd heart) during development of l-NAME-induced hypertension.
2005 Published by Elsevier Ltd.
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. Introduction
Despite the fact that essential hypertension is one of the
ost prevalent diseases and an important risk factor for car-
iovascular morbidity and mortality, the underlying patho-
hysiological abnormalities leading to the development of the
levated arterial pressure in this disorders remain elusive [22].
In normal blood vessels, endothelium-derived nitric oxide
NO) is continuously released both luminally and ablumi-
ally, protecting against platelet aggregation and adhesion
12,14] as well as influencing vascular smooth muscle tone
7,20]. NO is enzymatically synthesized from l-arginine, a
rocess that can be antagonized by substituted l-arginine
ompounds such as N-nitro-l-arginine methyl ester (l-
AME), which compete for the NO synthase [18]. Several
∗ Corresponding author. Tel.: +98 21 805 8696; fax: +98 21 805 8719.
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studies have demonstrated that blockade of NO synthesis
leads to a marked rises in systemic blood pressure (BP) [21],
suggesting that tonic release of NO controls BP in the resting
state. Rats chronically treated with l-NAME provide a new
model of hypertensive disease, with decreased NO synthase
activity as well as chronic decrease in the arterial wall cyclic
GMP content [3]. The NO synthesis blocker, l-NAME, is
water soluble and orally active and when given in the drink-
ing water to animals produces a prolonged increase in blood
pressure over many hours [6].
The renin angiotensin aldosterone system (RAAS) plays a
major physiologic role in blood pressure control and sodium
volume homeostasis [23]. This system has been suggested to
be of importance in pathologic conditions such as high blood
pressure and renal complications [17]. Angiotensin convert-
ing enzyme (ACE) is a zinc metallopeptidase which plays a
major role in regulation of vascular tone by converting the
inactive peptide, angiotensin I (Ang I) into vasoconstrictor
043-6618/$ – see front matter © 2005 Published by Elsevier Ltd.
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and trophic angiotensin II (Ang II) [15]. The octapeptide Ang
II is the active component of the renin–angiotensin system
(RAS) and has a major role in the regulation of cardiovas-
cular, renal and endocrine functions [8]. ACE exists both
as a membrane-bound enzyme in various organs such as
heart, blood vessels, kidney and in a freely soluble form in
plasma [11,28]. There are some reports suggesting that RAS
is altered in this model of chronic administration of l-NAME
[1,27]. It has been shown that blockade of the RAS with a
converting enzyme inhibitor [13], or with an angiotensin II
(Ang II) receptor antagonist [19] prevents the elevation of
BP in l-NAME-treated animals. It has also been reported
that gene expression of angiotensin II receptor increased in
l-NAME-received animals [5]. Furthermore, several reports
have shown that NO antagonizes the biological function of
Ang II, such as migration of vascular smooth muscle cells
[11]. However, less is known about alterations of serum and
tissue ACE activity during development of l-NAME-induced
hypertension. In this study, the role of ACE activity in serum
and various organs including kidney, heart, aorta and lung
were investigated during development of hypertension and
particularly the correlation between this enzyme activity and
structural changes in the aorta of l-NAME-treated animals
were also been examined.
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fatty and connective tissues, blotted dry and then weighted.
ACE activity was measured as described by Horiuchi et al.
[9]. Tissues were homogenized at 4 ◦C in cold Trizma–HCl
buffer (pH 7.8) containing 30 mM KCl, 5 mM magnesium
acetate, 0.25 M sucrose and 1% of Triton X-100 (Sigma).
The homogenate was centrifuged at 5000 × g for 15 min at
4 ◦C and supernatant was used for assay. Serums and super-
natants of centrifuged samples were kept frozen at −80 ◦C
until assayed.
ACE activity was determined by high performance liq-
uid chromatography (HPLC). Briefly 40l of borate buffer
containing 3.5 mM P-benzoyl-l-glycyl-l-leucine (Hip-His-
Leu, Sigma) as substrate was added to the 10l of sample
and incubate at 37 ◦C for 30 min with constant shaking. The
reaction was stopped by addition of 150l of methaphos-
phoric acid and then was centrifuged at 2000 × g for 5 min
and 20l of supernatant was injected into the column and the
amount of hippuric acid liberated from the substrate was ana-
lyzed by HPLC. One unit of activity is defined as the amount
of enzyme catalyzing the release of 1M of hippuric acid
from Hip-His-Leu per minute at 37 ◦C under standard assay
conditions.
2.4. Histological evaluation
The thoracic aorta was dissected out, cleaned and fixed
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s. Material and methods
.1. Animals
Five groups of normotensive age-matched Sprague–
awley rats weighing 200–250 g were used in this study
n = 10). All of animals had free access to water and stan-
ard rat chow. The first group of rats received l-NAME
50 mg/100 ml, Sigma Chemical, St. Louis, MO, USA) in
he drinking water for 2 weeks (W1). Their daily intake of
-NAME was ∼50 mg kg−1. The other groups received the
ame amount of l-NAME for 4, 8 and 12 weeks correspond to
2, W3 and W4 groups, respectively. The respective control
roups received tap water for the same periods.
.2. Measurement of blood pressure
To assess the development of hypertension, indirect sys-
olic tail-cuff blood pressures were routinely obtained with
Narco Bio-systems Electro-Sphygmomanometer (Huston,
X, USA). The mean of three measurements was obtained
rom each rat once a week until the end of the experiment.
.3. Tissue preparation and measurement of ACE
ctivity
Blood samples were collected for measuring serum ACE
ctivity and rats were then sacrificed by decapitation under
ther general anesthesia. Kidney, heart, lung and a 1-cm seg-
ent of thoracic aorta were rapidly removed, cleaned ofn 10% formaline. The aortic tissue then were embedded in
araffin and sectioned into 8m thick sections and stained
ith hematoxylin–eosin (H&E) for light microscopic study.
he cross-sectional area (CSA) of aorta was evaluated from
hotographs of whole aortic ring sections taken at 40× mag-
ification and scanned, digitized and analyzed by computer,
sing the Adobe Photoshop Imaging program (Adobe System
ncorporation) [25].
.5. Statistical analysis
For SBP determination, the average of three measurements
as taken at the time of recording. The data presented was
he mean ± S.E.M. Average of blood pressure in each group
ompared to respective control group using an unpaired Stu-
ent t-test. Also comparison of heart weight (HW), and aortic
eight (AW) of l-NAME-induced hypertensive rats and their
ge-matched controls were made by unpaired Student t-test.
Multiple comparisons of tissues and serum ACE activity
ith their control values were made using one-way analysis
f variance (ANOVA). The relationship between variables
as assessed by a simple linear regression analysis. Values
f P < 0.05 were considered statistically significant.
. Results
.1. Blood pressure and tissue weight
Time-related changes in systolic arterial pressure are
hown in Fig. 1. In l-NAME-treated animals, the SBP
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Fig. 1. Time-related changes in systolic arterial pressure in control (CTL)
and l-NAME-received animals for 2, 4, 8 and 12 weeks correspond
to W1, W2, W3 and W4 groups, respectively. Values are expressed as
mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the C group.
increased progressively, but no significant elevation in SBP
was observed at 2 weeks after l-NAME administration com-
pared to control. The SBP significantly enhanced in W2
and W3 groups (P < 0.05, P < 0.01, respectively) and reached
to highest level during 12 weeks after l-NAME treatment
(P < 0.001).
Fig. 2. Angiotensin-converting enzyme (ACE) activity (mol/min g) of
serum in control (CTL) and l-NAME-received animals for 2, 4, 8 and 12
weeks correspond to W1, W2, W3 and W4 groups. Values are expressed as
mean ± S.E.M. (n = 10).
3.2. Serum and tissue ACE activity
ACE activity determined in serum from hypertensive rats
taken at 2, 4, 8 and 12 weeks after l-NAME treatment was
similar to that of normotensive control rats (Fig. 2).
The local ACE activity in different tissues during devel-
opment of l-NAME-induced hypertension was measured
F
l
aig. 3. Angiotensin-converting enzyme (ACE) activity (mol/min g) of tissues inc
-NAME-received animals for 2, 4, 8 and 12 weeks correspond to W1, W2, W3 an
nd ***P < 0.001 when compared to respective control groups (n = 10).luding aorta (A), heart (B), lung (C) and kidney (D) in control (CTL) and
d W4 groups. Values are expressed as mean ± S.E.M. *P < 0.05, **P < 0.01
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Fig. 4. Correlation between blood pressure and heart (A) and aortae (B) angiotensin-converting enzyme (ACE) activity in l-NAME-received animals for 2, 4,
8 and 12 weeks correspond to W1, W2, W3 and W4 groups, respectively (n = 10). Aortic ACE activity vs. blood pressure, P < 0.001 and heart ACE activity vs.
blood pressure, P < 0.001.
(Fig. 3), in which ACE activity in aorta and heart
homogenates but not in lung and kidney markedly increased
in parallel to elevation of blood pressure. Also there was
a positive correlation between elevation of blood pressure
and alteration of ACE activity in the aortae and hearts of
l-NAME-induced hypertensive rats (Fig. 4). The correlation
coefficients between ACE activity and augmentation of blood
pressure were 0.92 and 0.99 for aorta and heart, respectively.
F
(
(ig. 5. (a) Bar graphs show the CSA of thoracic sections of 10 rats per groups. Valu
b) Micrographs of cross-sectional area (CSA) of thoracic aorta (original magnific
W3), and (C) l-NAME-treated rats at 12 weeks (W4).es are expressed as mean ± S.E.M. *P < 0.05, **P < 0.01 vs. control group.
ation 40×) from (A) control group, (B) l-NAME-treated rats at 8 weeks
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Table 1
Comparison of body weight (BW), heart weight (HW), and aortic weight (AW) of l-NAME-induced hypertensive rats during 2, 4, 8 and 12 weeks and
age-matched controls (CTL)
Time (weeks)
2 4 8 12
CTL l-NAME CTL l-NAME CTL l-NAME CTL l-NAME
BW (g) 240 ± 2.9 231 ± 4.6 268 ± 3.3 273 ± 5.2 319 ± 7.9 332 ± 9.1 347 ± 9.9 360 ± 8.7
AW (mg) 44 ± 2.3 59 ± 1.9 47 ± 3.0 72 ± 2.9* 51 ± 1.1 93 ± 3.4* 54 ± 2.4 1.13 ± 3.6**
HW (mg) 622 ± 9.0 693 ± 11 629 ± 10 946 ± 15* 638 ± 18 1263 ± 19** 643 ± 16 1396 ± 22**
Data are presented as mean ± S.E.M.
* P < 0.05.
** P < 0.01 vs. control group.
Fig. 6. Correlation between aortic cross-sectional area (CSA) and blood pressure (A) and aortic ACE activity (B) angiotensin-converting enzyme (ACE) activity
in l-NAME-received animals for 2, 4, 8 and 12 weeks correspond to W1, W2, W3 and W4 groups, respectively (n = 10). Aortic CSA vs. blood pressure, P < 0.01
and aortic CSA vs. ACE activity, P < 0.01.
3.3. Tissue weight
The heart and aortic weight significantly increased dur-
ing development of chronic NO-blockade while body weight
did not show marked alterations in hypertensive animals
(Table 1).
The aortic CSA (mm2) was increased inl-NAME-induced
hypertensive animals (Fig. 5a). It was significantly greater in
W2 (P < 0.05), W3 (P < 0.01) and W4 (P < 0.001) l-NAME-
induced rats compared to controls and was correlated with
augmentation of aortic ACE activity and amount of blood
pressure during development of hypertension (Fig. 6).
4. Discussion
This study investigates the alterations of ACE activity in
serum as well as other tissues including heart, aorta, kid-
ney and lung during 2, 4, 8 and 12 weeks after l-NAME-
induced hypertension in rats. The structural changes of aorta
were also evaluated during development of hypertension.
In present study, the major finding was the augmentation
of ACE activity in cardiac and aortic tissues during devel-
opment of l-NAME-induced non-renin-dependent hyper-
tension, while serum, kidney and lung ACE activity was
unchanged.
It is now well recognized that the renin–angiotensin sys-
tem is not only an endocrine system, but also most of its
components are generated or activated in several tissues. It
has previously been demonstrated by our group that local
ACE activity was elevated in various organs of two-kidney,
one-clip (2K1C), a renin-dependent and one-kidney, one-
clip (1K1C), a non-renin-dependent model of hypertension
[24,29]. In addition to that, the major role of vascular ACE
activity has also been previously reported in spontaneously
hypertensive rats [17].
It has widely been shown that long-term administration of
l-NAME in rats could decrease NO synthesis and cause arte-
rial hypertension [21]. The present study demonstrated that
the structural changes in aorta started from fourth week of l-
NAME administration, which was correlated with elevation
of aortic ACE activity (Fig. 3A). Thus, long-term adminis-
tration of l-NAME cause greater wall-to-lumen ratio in aorta
and possibly activation of aortic ACE preceded the develop-
ment of structural changes induced by higher angiotensin II.
Such evidences suggest that inhibition of activated ACE may
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explain the benefits of ACEI in lowering blood pressure of
NO-blocked animals [13,19].
These findings are in agreement with previous reports
which demonstrated development of vascular structural
changes and cardiac hypertrophy with increased ACE activity
[2]. In the present study, tissue ACE activities were increased
only in the heart and aorta but not in other organs examined. A
significant correlation was also been observed between aortic
structural changes and ACE activity (Fig. 6).
It has been demonstrated that nitric oxide decrease vas-
cular response to Ang II through cGMP production [26];
conversely acute blockade of NO synthase enhances the
response to Ang II [10]. Hence, it appears that both a
reduced production of nitric oxide and an enhanced release
of vasoconstriction factors such as Ang II contribute to the
impaired endothelium-dependent relaxations in l-NAME-
induced hypertensive rats.
Previous investigations considered two pathophysiologi-
cal stages for l-NAME-induced hypertension. First, an early
stage in which SBP is high but there are no changes in
the renin activity and there is no cardiovascular hypertro-
phy [16,2]. In the later stage, there is a gradual elevation
of renin activity associated with structural damage in vas-
culature of the kidney and central nervous system leading
the death [16]. Our results in agreement with previous find-
ings have shown that cardiac and aortic ACE activity (but
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